{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:48:30Z","timestamp":1794620910185,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41401-021-00725-1","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T06:04:43Z","timestamp":1627884283000},"page":"941-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis"],"prefix":"10.1038","volume":"43","author":[{"given":"He-ming","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-jie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-cui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"725_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology."},{"key":"725_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577\u201386.","journal-title":"Hepatology."},{"key":"725_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Zobair Y, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333.","journal-title":"Hepatology."},{"key":"725_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69:896\u2013904.","journal-title":"J Hepatol"},{"key":"725_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","volume":"10","author":"A Wree","year":"2013","unstructured":"Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627\u201336.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"725_CR6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3748\/wjg.v24.i14.1491","volume":"24","author":"I Mikolasevic","year":"2018","unstructured":"Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, et al. Nonalcoholic fatty liver disease and liver transplantation\u2014where do we stand? World J Gastroenterol. 2018;24:1491\u2013506.","journal-title":"World J Gastroenterol"},{"key":"725_CR7","doi-asserted-by":"publisher","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","volume":"302","author":"K Miura","year":"2012","unstructured":"Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1310\u2013G1321.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"725_CR8","doi-asserted-by":"publisher","first-page":"e92902","DOI":"10.1172\/jci.insight.92902","volume":"16","author":"M Itoh","year":"2017","unstructured":"Itoh M, Suganami T, Kato H, Kanai S, Shirakawa I, Sakai T, et al. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight. 2017;16:e92902.","journal-title":"JCI Insight"},{"key":"725_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127:55\u201364.","journal-title":"J Clin Invest"},{"key":"725_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","volume":"13","author":"E Seki","year":"2007","unstructured":"Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324\u201332.","journal-title":"Nat Med"},{"key":"725_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377\u201386.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"725_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jhep.2011.10.026","volume":"56","author":"P Ramachandran","year":"2012","unstructured":"Ramachandran P, Iredale JP. Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution. J Hepatol. 2012;56:1417\u20139.","journal-title":"J Hepatol"},{"key":"725_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/hep.26429","volume":"58","author":"J-P Pradere","year":"2013","unstructured":"Pradere J-P, Kluwe J, De Minicis S, Jiao J-J, Gwak G-Y, Dapito DH, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013;58:1461\u201373.","journal-title":"Hepatology."},{"key":"725_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2010.03.052","volume":"139","author":"K Miura","year":"2010","unstructured":"Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139:323\u201334.","journal-title":"Gastroenterology."},{"key":"725_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2337\/db09-0016","volume":"59","author":"W Huang","year":"2010","unstructured":"Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes. 2010;59:347\u201357.","journal-title":"Diabetes."},{"key":"725_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbrc.2009.05.070","volume":"385","author":"AM Neyrinck","year":"2009","unstructured":"Neyrinck AM, Cani PD, Dewulf EM, De Backer F, Bindels LB, Delzenne NM. Critical role of Kupffer cells in the management of diet-induced diabetes and obesity. Biochem Biophys Res Commun. 2009;385:351\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"725_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.22952","volume":"50","author":"E Seki","year":"2009","unstructured":"Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50:185\u201397.","journal-title":"Hepatology."},{"key":"725_CR18","first-page":"1858","volume":"119","author":"E Seki","year":"2009","unstructured":"Seki E, De Minicis S, Gwak G-Y, Kluwe J, Inokuchi S, Bursill CA, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119:1858\u201370.","journal-title":"J Clin Invest"},{"key":"725_CR19","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1172\/JCI41732","volume":"120","author":"M-L Berres","year":"2010","unstructured":"Berres M-L, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010;120:4129\u201340.","journal-title":"J Clin Invest"},{"key":"725_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","volume":"47","author":"S Friedman","year":"2016","unstructured":"Friedman S, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016;47:356\u201365.","journal-title":"Contemp Clin Trials"},{"key":"725_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrd.2015.3","volume":"15","author":"G Musso","year":"2016","unstructured":"Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249\u201374.","journal-title":"Nat Rev Drug Discov"},{"key":"725_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bpg.2011.02.007","volume":"25","author":"V Zimmer","year":"2011","unstructured":"Zimmer V, Lammert F. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol. 2011;25:269\u201380.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"725_CR23","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Prim. 2015;1:15080.","journal-title":"Nat Rev Dis Prim"},{"key":"725_CR24","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/hep.29127","volume":"65","author":"Z Fan","year":"2017","unstructured":"Fan Z, Li L, Li M, Zhang X, Hao C, Yu L, et al. The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice. Hepatology. 2017;65:1904\u201319.","journal-title":"Hepatology."},{"key":"725_CR25","first-page":"26","volume":"21","author":"S Horsburgh","year":"2015","unstructured":"Horsburgh S, Robson-Ansley P, Adams R, Smith C. Exercise and inflammation-related epigenetic modifications: focus on DNA methylation. Exerc Immunol Rev. 2015;21:26\u201341.","journal-title":"Exerc Immunol Rev"},{"key":"725_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/ajmg.b.32567","volume":"174","author":"R Alam","year":"2017","unstructured":"Alam R, Abdolmaleky HM, Zhou JR. Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet B Neuropsychiatr Genet. 2017;174:651\u201360.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"725_CR27","doi-asserted-by":"publisher","first-page":"8344","DOI":"10.7150\/thno.30707","volume":"9","author":"JJ Peng","year":"2019","unstructured":"Peng JJ, Li JC, Huang J, Xu P, Huang HH, Liu YJ, et al. p300\/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization. Theranostics. 2019;9:8344\u201361.","journal-title":"Theranostics."},{"key":"725_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810\u201320.","journal-title":"Hepatology."},{"key":"725_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/hep.21752","volume":"46","author":"S Joshi-Barve","year":"2007","unstructured":"Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology. 2007;46:823\u201330.","journal-title":"Hepatology."},{"key":"725_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","volume":"24","author":"X Wang","year":"2016","unstructured":"Wang X, Zheng Z, Caviglia JM, Corey KE, Herfel TM, Cai B, et al. Hepatocyte TAZ\/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab. 2016;24:848\u201362.","journal-title":"Cell Metab"},{"key":"725_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1146\/annurev-pharmtox-010617-052545","volume":"58","author":"J Wattacheril","year":"2018","unstructured":"Wattacheril J, Issa D, Sanyal A. Nonalcoholic steatohepatitis (NASH) and hepatic fibrosis: emerging therapies. Annu Rev Pharmacol Toxicol. 2018;58:649\u201362.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"725_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","volume":"22","author":"CC Lindenmeyer","year":"2018","unstructured":"Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018;22:11\u201321.","journal-title":"Clin Liver Dis"},{"key":"725_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"S Sutti","year":"2020","unstructured":"Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17:81\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"725_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/13543784.2020.1703949","volume":"29","author":"K Qureshi","year":"2020","unstructured":"Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs. 2020;29:151\u201361.","journal-title":"Expert Opin Investig Drugs"},{"key":"725_CR35","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541\u201352.","journal-title":"Oncogene."},{"key":"725_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/thoraxjnl-2014-206411","volume":"70","author":"M Korfei","year":"2015","unstructured":"Korfei M, Skwarna S, Henneke I, MacKenzie B, Klymenko O, Saito S, et al. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax. 2015;70:1022\u201332.","journal-title":"Thorax."},{"key":"725_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","volume":"11","author":"F Leoni","year":"2005","unstructured":"Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med.\u00a02005;11:1\u201315.","journal-title":"Mol Med"},{"key":"725_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D\u2019Oria V, D\u2019Amico A, Catteruccia M, Pane M, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:643\u20139.","journal-title":"Neuromuscul Disord"},{"key":"725_CR39","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1016\/j.ajpath.2016.08.001","volume":"186","author":"CK Singh","year":"2016","unstructured":"Singh CK, Nihal M, Ahmad N. Histone deacetylase inhibitory approaches for the management of osteoarthritis. Am J Pathol. 2016;186:2555\u20138.","journal-title":"Am J Pathol"},{"key":"725_CR40","doi-asserted-by":"publisher","first-page":"e13500","DOI":"10.1111\/nmo.13500","volume":"31","author":"T Louwies","year":"2019","unstructured":"Louwies T, Ligon CO, Johnson AC, Greenwood-Van Meerveld B. Targeting epigenetic mechanisms for chronic visceral pain: a valid approach for the development of novel therapeutics. Neurogastroenterol Motil. 2019;31:e13500.","journal-title":"Neurogastroenterol Motil"},{"key":"725_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nm.4290","volume":"23","author":"PX Wang","year":"2017","unstructured":"Wang PX, Ji YX, Zhang XJ, Zhao LP, Yan ZZ, Zhang P, et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med. 2017;23:439\u201349.","journal-title":"Nat Med"},{"key":"725_CR42","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1074\/jbc.M807616200","volume":"284","author":"ZZ Li","year":"2009","unstructured":"Li ZZ, Berk M, McIntyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem. 2009;284:5637\u201344.","journal-title":"J Biol Chem"},{"key":"725_CR43","first-page":"259","volume":"14","author":"RA Sinha","year":"2018","unstructured":"Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. NatRev Endocrinol. 2018;14:259\u201369.","journal-title":"NatRev Endocrinol"},{"key":"725_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","volume":"30","author":"Z Chen","year":"2019","unstructured":"Chen Z, Yu Y, Cai J, Li H. Emerging molecular targets for treatment of nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2019;30:903\u201314.","journal-title":"Trends Endocrinol Metab"},{"key":"725_CR45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jceh.2019.06.003","volume":"9","author":"S Kothari","year":"2019","unstructured":"Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9:723\u201330.","journal-title":"J Clin Exp Hepatol"},{"key":"725_CR46","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","volume":"17","author":"L Adorini","year":"2012","unstructured":"Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988\u201397.","journal-title":"Drug Discov Today"},{"key":"725_CR47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","volume":"67","author":"O Krenkel","year":"2018","unstructured":"Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018;67:1270\u201383.","journal-title":"Hepatology."},{"key":"725_CR48","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","volume":"67","author":"R Loomba","year":"2018","unstructured":"Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67:549\u201359.","journal-title":"Hepatology."},{"key":"725_CR49","doi-asserted-by":"publisher","first-page":"158594","DOI":"10.1016\/j.bbalip.2019.158594","volume":"1865","author":"A Ferrari","year":"2020","unstructured":"Ferrari A, Longo R, Peri C, Coppi L, Caruso D, Mai A, et al. Inhibition of class I HDACs imprints adipogenesis toward oxidative and brown-like phenotype. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158594.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"725_CR50","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1016\/j.celrep.2016.08.005","volume":"16","author":"V Gaur","year":"2016","unstructured":"Gaur V, Connor T, Sanigorski A, Martin SD, Bruce CR, Henstridge DC, et al. Disruption of the class IIa HDAC corepressor complex increases energy expenditure and lipid oxidation. Cell Rep. 2016;16:2802\u201310.","journal-title":"Cell Rep"},{"key":"725_CR51","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/ijms21041297","volume":"21","author":"C Tonini","year":"2020","unstructured":"Tonini C, Colardo M, Colella B, Di Bartolomeo S, Berardinelli F, Caretti G, et al. Inhibition of bromodomain and extraterminal domain (BET) proteins by JQ1 unravels a novel epigenetic modulation to control lipid homeostasis. Int J Mol Sci.\u00a02020;21:1297.","journal-title":"Int J Mol Sci"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00725-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T23:21:30Z","timestamp":1666999290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00725-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00725-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.09.141655","asserted-by":"object"}]},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"3 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}